HAVCR2 and glioma: Interestingly, another group identified significantly greater percentage of TIM-3 positivity on peripheral CD14+ monocytes from glioma patients versus healthy donors and glioma patients with higher percentage of TIM-3 positivity on CD14+ monocytes having a higher risk for tumor recurrence or death [70].